Stacy Ku
Stock Analyst at TD Cowen
(3.03)
# 2,616
Out of 5,078 analysts
135
Total ratings
45%
Success rate
2.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stacy Ku
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCRX BioCryst Pharmaceuticals | Reiterated: Buy | $30 | $7.65 | +292.16% | 18 | Oct 21, 2026 | |
| LENZ LENZ Therapeutics | Reiterated: Buy | $60 → $50 | $3.16 | +1,482.28% | 19 | Oct 21, 2026 | |
| SUPN Supernus Pharmaceuticals | Reiterated: Buy | $65 | $40.70 | +59.71% | 22 | Oct 21, 2026 | |
| TNXP Tonix Pharmaceuticals Holding | Reiterated: Buy | $22 | $5.17 | +325.53% | 5 | Oct 21, 2026 | |
| VRCA Verrica Pharmaceuticals | Reiterated: Buy | $20 | $3.53 | +466.57% | 16 | Oct 21, 2026 | |
| AUPH Aurinia Pharmaceuticals | Reiterated: Buy | $17 | $16.86 | +0.83% | 17 | Aug 19, 2026 | |
| YARW Yarrow Bioscience | Initiated Coverage: Buy | n/a | $19.27 | - | 9 | Jul 27, 2026 | |
| AVTX Avalo Therapeutics | Reiterated: Buy | n/a | $6.93 | - | 4 | Jun 11, 2026 | |
| SLGL Sol-Gel Technologies | Initiated Coverage: Buy | n/a | $69.45 | - | 1 | May 29, 2026 | |
| TARA Protara Therapeutics | Rated: Buy | $30 | $2.33 | +1,187.55% | 14 | May 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $12 → $8 | $1.93 | +314.51% | 2 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $165 → $175 | $151.91 | +15.20% | 6 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $8.72 | - | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $11.85 | n/a | 1 | Feb 26, 2025 |
BioCryst Pharmaceuticals
Oct 21, 2026
Reiterated: Buy
Price Target: $30
Current: $7.65
Upside: +292.16%
LENZ Therapeutics
Oct 21, 2026
Reiterated: Buy
Price Target: $60 → $50
Current: $3.16
Upside: +1,482.28%
Supernus Pharmaceuticals
Oct 21, 2026
Reiterated: Buy
Price Target: $65
Current: $40.70
Upside: +59.71%
Tonix Pharmaceuticals Holding
Oct 21, 2026
Reiterated: Buy
Price Target: $22
Current: $5.17
Upside: +325.53%
Verrica Pharmaceuticals
Oct 21, 2026
Reiterated: Buy
Price Target: $20
Current: $3.53
Upside: +466.57%
Aurinia Pharmaceuticals
Aug 19, 2026
Reiterated: Buy
Price Target: $17
Current: $16.86
Upside: +0.83%
Yarrow Bioscience
Jul 27, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $19.27
Upside: -
Avalo Therapeutics
Jun 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $6.93
Upside: -
Sol-Gel Technologies
May 29, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $69.45
Upside: -
Protara Therapeutics
May 20, 2026
Rated: Buy
Price Target: $30
Current: $2.33
Upside: +1,187.55%
Apr 23, 2026
Rated: Buy
Price Target: $12 → $8
Current: $1.93
Upside: +314.51%
Mar 13, 2026
Reiterated: Buy
Price Target: $165 → $175
Current: $151.91
Upside: +15.20%
Oct 30, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $8.72
Upside: -
Feb 26, 2025
Reiterated: Buy
Price Target: n/a
Current: $11.85
Upside: n/a